2024
A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
Sela I, Lahav C, Lowenthal G, Harel M, Elon Y, Yellin B, Dicker A, Halaban R, Marte J, Sznol M, Gulley J. A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Journal Of Clinical Oncology 2024, 42: 2568-2568. DOI: 10.1200/jco.2024.42.16_suppl.2568.Peer-Reviewed Original ResearchNon-small cell lung cancerHPV-related cancersProgression-free survivalPre-treatment plasma samplesInhibitor-based therapySquamous cell carcinomaPD-(L)1Overall survivalCell carcinomaCancer typesClinical benefitImmune checkpoint inhibitor (ICI)-based therapyMetastatic non-small cell lung cancerHead and neck squamous cell carcinomaAnogenital squamous cell carcinomasHazard ratioPD-1 inhibitor monotherapyNeck squamous cell carcinomaMultivariate Cox proportional hazards modelPredicting clinical benefitImmune checkpoint inhibitorsECOG performance statusInhibitor combination therapyPlasma samplesKaplan-Meier method
2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Journal Of Translational Medicine 2014, 12: 277. PMID: 25348889, PMCID: PMC4232645, DOI: 10.1186/s12967-014-0277-z.Peer-Reviewed Original ResearchConceptsProlong progression-free survivalOverall survivalMelanoma patientsMetastatic melanomaPathway inhibitorTumor microenvironmentImmune-modulating antibodiesLigand 1 pathwayMelanoma Bridge meetingProgression-free survivalMetastatic melanoma patientsCell death 1Adoptive cell transferNovel therapeutic targetContemporary clinical managementImportance of biomarkersFuture drug developmentMitogen-activated protein kinase pathway inhibitorsDifferent immunotherapiesImmune inhibitoryMelanoma BridgeDurable responsesSystemic therapyDeath-1Immune therapy